Yuichiro Ogura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7386755/publications.pdf

Version: 2024-02-01

49 papers

5,609 citations

249298 26 h-index 252626 46 g-index

52 all docs 52 docs citations

times ranked

52

4249 citing authors

#	Article	IF	CITATIONS
1	Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. British Journal of Ophthalmology, 2022, 106, 994-999.	2.1	34
2	Recommendations for OCT Angiography Reporting in Retinal Vascular Disease. Ophthalmology Retina, 2022, 6, 753-761.	1.2	16
3	HAWK and HARRIER. Ophthalmology, 2021, 128, 89-99.	2.5	215
4	Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database. Japanese Journal of Ophthalmology, 2021, 65, 215-226.	0.9	6
5	Cytoplasmic synthesis of endogenous <i>Alu</i> complementary DNA via reverse transcription and implications in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	3. 3	36
6	Remote screening of diabetic retinopathy using ultra-widefield retinal imaging. Diabetes Research and Clinical Practice, 2021, 177, 108902.	1.1	5
7	Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY). Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, , 1.	1.0	8
8	HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 72-84.	2.5	551
9	Macular hole and serous pigment epithelial detachment in bilateral acquired vitelliform lesions. American Journal of Ophthalmology Case Reports, 2020, 18, 100628.	0.4	1
10	Current practice in the management of branch retinal vein occlusion in Japan: Survey results of retina specialists in Japan. Japanese Journal of Ophthalmology, 2019, 63, 365-373.	0.9	14
11	Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies. Ophthalmology Retina, 2019, 3, 553-560.	1.2	4
12	Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Japanese Journal of Ophthalmology, 2019, 63, 243-254.	0.9	16
13	Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study. JAMA Ophthalmology, 2018, 136, 786.	1.4	186
14	Management of diabetic macular edema in Japan: a review and expert opinion. Japanese Journal of Ophthalmology, 2018, 62, 1-23.	0.9	44
15	Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists. Japanese Journal of Ophthalmology, 2017, 61, 43-50.	0.9	30
16	Integrated results from the COPERNICUS and GALILEO studies. Clinical Ophthalmology, 2017, Volume 11, 1533-1540.	0.9	28
17	Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Progress in Retinal and Eye Research, 2016, 53, 107-139.	7.3	276
18	Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Scientific Reports, 2016, 6, 29445.	1.6	35

#	Article	IF	Citations
19	Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. Japanese Journal of Ophthalmology, 2016, 60, 179-186.	0.9	6
20	Reply. American Journal of Ophthalmology, 2015, 159, 608.	1.7	0
21	Intravitreal Aflibercept Injection for MacularÂEdema Resulting from Central Retinal VeinÂOcclusion. Ophthalmology, 2014, 121, 202-208.	2.5	243
22	Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study. American Journal of Ophthalmology, 2014, 158, 1032-1038.e2.	1.7	142
23	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. Ophthalmology, 2014, 121, 193-201.	2.5	693
24	VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology, 2013, 97, 278-284.	2.1	196
25	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 2537-2548.	2.5	1,947
26	Lipid Hydroperoxide Induced Leukocyte–Endothelium Interaction in the Retinal Microcirculation. , 2012, , 545-557.		0
27	Pitavastatin Attenuates Leukocyte-Endothelial Interactions Induced by Ischemia-Reperfusion Injury in the Rat Retina. Current Eye Research, 2009, 34, 10-17.	0.7	10
28	Effect of Posterior Sub-Tenon Administration of Triamcinolone Acetonide on Leukocyte Dynamics in Rat Retinal Microcirculation after Panretinal Photocoagulation., 2008, 49, 2127.		10
29	Development of drug-delivery systems to the posterior segments of the eye. Expert Review of Ophthalmology, 2007, 2, 197-211.	0.3	2
30	Management System of Paper-Based Critical Pathways Developed in Each Hospital: Comparison between Medical School Hospital and General Hospital. , 2007, , .		0
31	Drug delivery from ocular implants. Expert Opinion on Drug Delivery, 2006, 3, 261-273.	2.4	70
32	Protective effect of polyethylene glycol-superoxide dismutase on leukocyte dynamics in rat retinal microcirculation under lipid hydroperoxide-induced oxidative stress. Experimental Eye Research, 2005, 81, 193-199.	1.2	14
33	Drug delivery systems for vitreoretinal diseases. Progress in Retinal and Eye Research, 2004, 23, 253-281.	7.3	194
34	Lipid Hydroperoxide Stimulates Leukocyte–Endothelium Interaction in the Retinal Microcirculation. Experimental Eye Research, 2002, 75, 69-75.	1.2	36
35	Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits., 2002, 240, 672-678.		22
36	Drug delivery to the posterior segments of the eye. Advanced Drug Delivery Reviews, 2001, 52, 1-3.	6.6	23

3

Yuichiro Ogura

#	Article	IF	CITATION
37	Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. Journal of Controlled Release, 2000, 68, 263-271.	4.8	84
38	Protective Effects of Selectin Ligands/Inhibitor (SKK-60060) against Retinal Ischemia-Reperfusion Injury. Experimental Eye Research, 2000, 71, 283-293.	1.2	16
39	Active drug targeting with immunoconjugates to choroidal neovascularization. Current Eye Research, 2000, 21, 952-961.	0.7	29
40	Equator ring efficacy in maintaining capsular bag integrity and transparency after cataract removal in monkey eyes. Graefe's Archive for Clinical and Experimental Ophthalmology, 1998, 236, 375-379.	1.0	25
41	Biodegradable scleral implant for intravitreal controlled release of fluconazole. Current Eye Research, 1997, 16, 930-935.	0.7	45
42	Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Current Eye Research, 1997, 16, 633-639.	0.7	36
43	A new fluorescent imaging procedurein vivofor evaluation of the retinal microcirculation in rats. Current Eye Research, 1995, 14, 223-228.	0.7	31
44	Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. Journal of Controlled Release, 1995, 37, 143-150.	4.8	62
45	Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Current Eye Research, 1995, 14, 473-477.	0.7	33
46	Feasibility of drug targeting to the retinal pigment epithelium with biodegradable microspheres. Current Eye Research, 1994, 13, 171-176.	0.7	26
47	<i>In vitro</i> phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Current Eye Research, 1994, 13, 353-360.	0.7	44
48	Tissue reactions induced by modified poly(vinyl alcohol) hydrogels in rabbit cornea. Journal of Biomedical Materials Research Part B, 1992, 26, 1583-1598.	3.0	11
49	Collagen-immobilized hydrogel as material for lamellar keratoplasty. Journal of Applied Biomaterials:	1.1	27